Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide

Yi Luan, Maxwell E. Edmonds, Teresa K. Woodruff, So Youn Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cancer therapy can cause off-target effects including ovarian damage, which may result in primary ovarian insufficiency in girls and premenopausal women. Loss of ovarian follicles within the ovarian reserve leads to ovarian endocrine dysfunction and impaired fertility. Cyclophosphamide (CPA), a commonly used chemotherapeutic and immunosuppressant agent, is a gonadotoxic agent that destroys ovarian cells by crosslinking DNA. To protect the ovary against CPA damage, we sought to precisely map the mechanism by which the ovarian reserve is depleted by CPA. We found that CPA specifically depletes primordial follicles without affecting primary and secondary follicles in three independent murine strains (CD-1, C57BL/6J and BALB/cJ) in vivo. We directly tested the effect of the active metabolite of CPA, 1 μM 4-hydroxyperoxycyclophophamide (4-HC), in vitro and confirmed the loss of primordial oocytes but no change in the number of primary and secondary follicles. We demonstrated that phospho-AKT (p-AKT) and cleaved PARP (cPARP) are present in primordial oocytes 3 days after CPA injection, consistent with the role of these markers as part of the apoptotic cascade. Interestingly, p-AKT positive primordial oocytes co-expressed cPARP. Treatment of animals with specific inhibitors of apoptotic pathway components, ETP46464 and CHK2, blocked 4-HC‒induced DNA damage in vitro. These data suggest that CPA targets primordial germ cells in the ovarian reserve by stimulating apoptosis pathways. Adjuvant therapies to protect primordial germ cells from the off-target effects of CPA may reduce the risk of POI.

Original languageEnglish (US)
Pages (from-to)243-256
Number of pages14
JournalJournal of Endocrinology
Volume240
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Cyclophosphamide
Apoptosis
Oocytes
Germ Cells
Primary Ovarian Insufficiency
Ovarian Follicle
Ovarian Reserve
Immunosuppressive Agents
DNA Damage
Fertility
Ovary
Therapeutics
Injections
DNA
Neoplasms

Keywords

  • Cancer
  • Ovary
  • Primary ovarian insufficiency
  • Primordial follicle

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide. / Luan, Yi; Edmonds, Maxwell E.; Woodruff, Teresa K.; Kim, So Youn.

In: Journal of Endocrinology, Vol. 240, No. 2, 01.02.2019, p. 243-256.

Research output: Contribution to journalArticle

Luan, Yi ; Edmonds, Maxwell E. ; Woodruff, Teresa K. ; Kim, So Youn. / Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide. In: Journal of Endocrinology. 2019 ; Vol. 240, No. 2. pp. 243-256.
@article{6a4eff5980334c34bab67b5579371dcf,
title = "Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide",
abstract = "Cancer therapy can cause off-target effects including ovarian damage, which may result in primary ovarian insufficiency in girls and premenopausal women. Loss of ovarian follicles within the ovarian reserve leads to ovarian endocrine dysfunction and impaired fertility. Cyclophosphamide (CPA), a commonly used chemotherapeutic and immunosuppressant agent, is a gonadotoxic agent that destroys ovarian cells by crosslinking DNA. To protect the ovary against CPA damage, we sought to precisely map the mechanism by which the ovarian reserve is depleted by CPA. We found that CPA specifically depletes primordial follicles without affecting primary and secondary follicles in three independent murine strains (CD-1, C57BL/6J and BALB/cJ) in vivo. We directly tested the effect of the active metabolite of CPA, 1 μM 4-hydroxyperoxycyclophophamide (4-HC), in vitro and confirmed the loss of primordial oocytes but no change in the number of primary and secondary follicles. We demonstrated that phospho-AKT (p-AKT) and cleaved PARP (cPARP) are present in primordial oocytes 3 days after CPA injection, consistent with the role of these markers as part of the apoptotic cascade. Interestingly, p-AKT positive primordial oocytes co-expressed cPARP. Treatment of animals with specific inhibitors of apoptotic pathway components, ETP46464 and CHK2, blocked 4-HC‒induced DNA damage in vitro. These data suggest that CPA targets primordial germ cells in the ovarian reserve by stimulating apoptosis pathways. Adjuvant therapies to protect primordial germ cells from the off-target effects of CPA may reduce the risk of POI.",
keywords = "Cancer, Ovary, Primary ovarian insufficiency, Primordial follicle",
author = "Yi Luan and Edmonds, {Maxwell E.} and Woodruff, {Teresa K.} and Kim, {So Youn}",
year = "2019",
month = "2",
day = "1",
doi = "10.1530/JOE-18-0370",
language = "English (US)",
volume = "240",
pages = "243--256",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "2",

}

TY - JOUR

T1 - Inhibitors of apoptosis protect the ovarian reserve from cyclophosphamide

AU - Luan, Yi

AU - Edmonds, Maxwell E.

AU - Woodruff, Teresa K.

AU - Kim, So Youn

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Cancer therapy can cause off-target effects including ovarian damage, which may result in primary ovarian insufficiency in girls and premenopausal women. Loss of ovarian follicles within the ovarian reserve leads to ovarian endocrine dysfunction and impaired fertility. Cyclophosphamide (CPA), a commonly used chemotherapeutic and immunosuppressant agent, is a gonadotoxic agent that destroys ovarian cells by crosslinking DNA. To protect the ovary against CPA damage, we sought to precisely map the mechanism by which the ovarian reserve is depleted by CPA. We found that CPA specifically depletes primordial follicles without affecting primary and secondary follicles in three independent murine strains (CD-1, C57BL/6J and BALB/cJ) in vivo. We directly tested the effect of the active metabolite of CPA, 1 μM 4-hydroxyperoxycyclophophamide (4-HC), in vitro and confirmed the loss of primordial oocytes but no change in the number of primary and secondary follicles. We demonstrated that phospho-AKT (p-AKT) and cleaved PARP (cPARP) are present in primordial oocytes 3 days after CPA injection, consistent with the role of these markers as part of the apoptotic cascade. Interestingly, p-AKT positive primordial oocytes co-expressed cPARP. Treatment of animals with specific inhibitors of apoptotic pathway components, ETP46464 and CHK2, blocked 4-HC‒induced DNA damage in vitro. These data suggest that CPA targets primordial germ cells in the ovarian reserve by stimulating apoptosis pathways. Adjuvant therapies to protect primordial germ cells from the off-target effects of CPA may reduce the risk of POI.

AB - Cancer therapy can cause off-target effects including ovarian damage, which may result in primary ovarian insufficiency in girls and premenopausal women. Loss of ovarian follicles within the ovarian reserve leads to ovarian endocrine dysfunction and impaired fertility. Cyclophosphamide (CPA), a commonly used chemotherapeutic and immunosuppressant agent, is a gonadotoxic agent that destroys ovarian cells by crosslinking DNA. To protect the ovary against CPA damage, we sought to precisely map the mechanism by which the ovarian reserve is depleted by CPA. We found that CPA specifically depletes primordial follicles without affecting primary and secondary follicles in three independent murine strains (CD-1, C57BL/6J and BALB/cJ) in vivo. We directly tested the effect of the active metabolite of CPA, 1 μM 4-hydroxyperoxycyclophophamide (4-HC), in vitro and confirmed the loss of primordial oocytes but no change in the number of primary and secondary follicles. We demonstrated that phospho-AKT (p-AKT) and cleaved PARP (cPARP) are present in primordial oocytes 3 days after CPA injection, consistent with the role of these markers as part of the apoptotic cascade. Interestingly, p-AKT positive primordial oocytes co-expressed cPARP. Treatment of animals with specific inhibitors of apoptotic pathway components, ETP46464 and CHK2, blocked 4-HC‒induced DNA damage in vitro. These data suggest that CPA targets primordial germ cells in the ovarian reserve by stimulating apoptosis pathways. Adjuvant therapies to protect primordial germ cells from the off-target effects of CPA may reduce the risk of POI.

KW - Cancer

KW - Ovary

KW - Primary ovarian insufficiency

KW - Primordial follicle

UR - http://www.scopus.com/inward/record.url?scp=85058611601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058611601&partnerID=8YFLogxK

U2 - 10.1530/JOE-18-0370

DO - 10.1530/JOE-18-0370

M3 - Article

C2 - 30530902

AN - SCOPUS:85058611601

VL - 240

SP - 243

EP - 256

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 2

ER -